Conversely, in patients with renal cancer who experience progression after initial treatment with sunitinib, sorafenib—a VEGF pathway inhibitor—has demonstrated superiority over tisorolimus, an mTOR pathway inhibitor. The gene discussed is MTOR; the disease is renal carcinoma.